Le Lézard
Classified in: Health, Science and technology

Company Profile for zPREDICTA, Inc.


zPREDICTA is the leading provider of tumor-specific 3D cell culture models for the in vitro testing of anti-cancer therapeutics. Our 3D cell culture models are tissue-specific and disease-specific thus offering higher predictive and analytical value than traditional 2D testing or non-specific 3D models. We provide in vitro testing services to some of the leading global biotechnology and pharmaceutical companies.

Company:

zPREDICTA, Inc.

 

 

Headquarters Address:

5941 Optical Court

 

San Jose, CA 95138

 

 

Main Telephone:

9178387648

 

 

Website:

www.zpredicta.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CFO: Tom Kelly

 

CEO: Julia Kirshner

 

 

CFO

 

Contact:

Tom Kelly

Phone:

9178387648

Email:

tom@zpredicta.com

 

 

CEO

 

Contact:

Julia Kirshner

Email:

julia@zpredicta.com

 


These press releases may also interest you

at 07:30
The "Global Autoimmune Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. Global Autoimmune Partnering 2014 to 2020 provides the full collection of Autoimmune disease deals signed...

at 07:25
Visionstate Corp. ("Visionstate" or "the Company") is pleased to announce it is collaborating with Bunzl Canada, the Company's exclusive distributor of its proprietary WandaNEXTtm solution, to further enhance its product line to meet the needs of...

at 07:15
The market value of healthcare software is forecasted to reach $29.9 billion by 2023, up from $19.5 billion in 2017. SoftwareDevelopmentCompany.co, a B2B marketplace connecting brands with software developers, identified the best developers who can...

at 07:12
Excelra, a leading global data and analytics company, today announced the release of the COVID-19 Drug Repurposing Database (https://www.excelra.com/covid-19-drug-repurposing-database/). The 'open-access' database presents a compilation of...

at 07:05
F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2tm) antibodies, today announces the publication of...

at 07:05
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced it has entered into a clinical collaboration agreement with Bristol Myers Squibb to evaluate the combination of NeoImmuneTech's NT-I7 (also known as...



News published on 27 february 2020 at 08:15 and distributed by: